StreetInsider.com News Articles

Form SCHEDULE 13D Passage BIO, Inc. Filed by: Lynx1 Capital Management LP

Thu, 02 Jul 2026 21:20:00 -0400

si-local-file:///var/storage/secattach/20260702/26730280.html

Form SCHEDULE 13D Passage BIO, Inc. Filed by: Lynx1 Capital Management LP

Thu, 02 Jul 2026 21:20:00 -0400

si-local-file:///var/storage/secattach/20260702/26730280.html

Form 4 Passage BIO, Inc. For: Jun 25 Filed by: Nichols Weston

Mon, 29 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260629/26706890.html

Form 4 Passage BIO, Inc. For: Jun 25 Filed by: Nichols Weston

Mon, 29 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260629/26706890.html

Form SCHEDULE 13G Passage BIO, Inc. Filed by: Baselake Partners, LP

Thu, 25 Jun 2026 18:45:00 -0400

si-local-file:///var/storage/secattach/20260625/26693785.html

Form SCHEDULE 13G Passage BIO, Inc. Filed by: Baselake Partners, LP

Thu, 25 Jun 2026 18:45:00 -0400

si-local-file:///var/storage/secattach/20260625/26693785.html

Form 425 Passage BIO, Inc. Filed by: Passage BIO, Inc.

Wed, 24 Jun 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260624/26686412.html

Form 425 Passage BIO, Inc. Filed by: Passage BIO, Inc.

Wed, 24 Jun 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260624/26686412.html

Form 8-K Passage BIO, Inc. For: Jun 23

Wed, 24 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260624/26685732.html

Form 8-K Passage BIO, Inc. For: Jun 23

Wed, 24 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260624/26685732.html

Form 425 Passage BIO, Inc. Filed by: Passage BIO, Inc.

Wed, 24 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260624/26685756.html

Form 425 Passage BIO, Inc. Filed by: Passage BIO, Inc.

Wed, 24 Jun 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260624/26685756.html

Passage Bio and Remix Therapeutics agree to all-stock merger deal

Wed, 24 Jun 2026 16:06:49 -0400

Passage Bio (NASDAQ: PASG) and Remix Therapeutics have entered into a definitive merger agreement to combine in an all-stock transaction, the companies announced June 24, 2026. The combined company plans to operate under the name Remix Therapeutics, Inc. and expects to trade on Nasdaq under the ticker symbol "RMTX."

Under the terms of the agreement, Passage Bio shareholders are expected to own approximately 7% of the combined company, while Remix stockholders — including investors participating in the concurrent financing — are expected to own approximately 93%. The ownership percentage for Passage Bio shareholders is subject to adjustment based on Passage Bio's

Passage Bio and Remix Therapeutics agree to all-stock merger deal

Wed, 24 Jun 2026 16:06:49 -0400

Passage Bio and Remix Therapeutics agree to all-stock merger deal

Wed, 24 Jun 2026 16:06:49 -0400

Passage Bio and Remix Therapeutics agree to all-stock merger deal

Wed, 24 Jun 2026 16:06:49 -0400

Passage Bio and Remix Therapeutics Announce Merger Agreement

Wed, 24 Jun 2026 16:05:00 -0400

Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin

Remix’s lead program, REM-422, is an orally available mRNA degrader targeting MYB, a historically undruggable transcription factor implicated across multiple cancers

Concurrent oversubscribed $100 million private placement financing of Remix expected to fund combined company operations into 2028, supporting delivery of several clinical readouts for REM-422 in 2027

Companies to hold joint conference call on June 24, 2026 at 4:30 PM ET

Passage Bio and Remix Therapeutics Announce Merger Agreement

Wed, 24 Jun 2026 16:05:00 -0400

Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin

Remix’s lead program, REM-422, is an orally available mRNA degrader targeting MYB, a historically undruggable transcription factor implicated across multiple cancers

Companies to hold joint conference call on June 24, 2026 at 4:30 PM ET

Passage Bio and Remix Therapeutics Announce Merger Agreement

Wed, 24 Jun 2026 16:05:00 -0400

Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin

Remix’s lead program, REM-422, is an orally available mRNA degrader targeting MYB, a historically undruggable transcription factor implicated across multiple cancers

Companies to hold joint conference call on June 24, 2026 at 4:30 PM ET

Passage Bio and Remix Therapeutics Announce Merger Agreement

Wed, 24 Jun 2026 16:05:00 -0400

Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin

Remix’s lead program, REM-422, is an orally available mRNA degrader targeting MYB, a historically undruggable transcription factor implicated across multiple cancers

Companies to hold joint conference call on June 24, 2026 at 4:30 PM ET

Guggenheim Downgrades Passage Bio Inc. (PASG) to Neutral

Wed, 10 Jun 2026 06:47:22 -0400

Guggenheim analyst Debjit Chattopadyaya downgraded Passage Bio Inc. (NASDAQ: PASG) from Buy to Neutral.

For an analyst ratings summary and ratings history on Passage Bio Inc. click here. For more ratings news on Passage Bio Inc. click here.

Shares of Passage Bio Inc. closed at $5.57 yesterday.

Passage Bio terminates collaboration deal, exits office lease

Wed, 27 May 2026 16:19:58 -0400

Passage Bio Inc. (NASDAQ: PASG) terminated its research collaboration agreement with Gemma Biotherapeutics Inc., providing written notice on May 21, 2026, according to a company statement.

The collaboration agreement, originally signed on July 31, 2024, involved Gemma conducting preclinical and Investigational New Drug-enabling work for Passage Bio's Huntington's disease research program and a paused Temporal Lobe Epilepsy program. Gemma had also granted Passage Bio options to conduct research programs in four central nervous system indications.

Separately, Passage Bio agreed to terminate its office lease at 2005 Market Street in Philadelphia, paying a $2.3 million termination fee to landlord Commerce Square Partners –

Form 8-K Passage BIO, Inc. For: May 21

Wed, 27 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260527/26558080.html

Form 8-K Passage BIO, Inc. For: May 21

Wed, 27 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260527/26558080.html

Form 8-K Passage BIO, Inc. For: May 19

Tue, 26 May 2026 07:15:00 -0400

si-local-file:///var/storage/secattach/20260526/26545794.html